57 related articles for article (PubMed ID: 18353621)
1. Severe epistaxis with tyrosine kinase inhibitors.
Hall PS; Kancherla K; Sastry PS; Brown JE
Clin Oncol (R Coll Radiol); 2008 May; 20(4):318-9. PubMed ID: 18353621
[No Abstract] [Full Text] [Related]
2. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
Bukowski RM
Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
[No Abstract] [Full Text] [Related]
3. Lower limbs erosions induced by sunitinib.
Kluger N; Chapelle A; Jacot W; Guillot B
Acta Derm Venereol; 2011 May; 91(3):360-1. PubMed ID: 21103845
[No Abstract] [Full Text] [Related]
4. Pyoderma gangrenosum with the use of sunitinib.
Nadauld LD; Miller MB; Srinivas S
J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
[No Abstract] [Full Text] [Related]
5. Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors.
Wolter P; Beuselinck B; Pans S; Schöffski P
Acta Oncol; 2009; 48(4):621-4. PubMed ID: 19107622
[No Abstract] [Full Text] [Related]
6. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
Pouessel D; Culine S
Eur Urol; 2008 Feb; 53(2):376-81. PubMed ID: 17825982
[TBL] [Abstract][Full Text] [Related]
7. Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib.
Chorianopoulos E; Jäger D; Katus HA; Frey N
Clin Res Cardiol; 2007 Nov; 96(11):829-30. PubMed ID: 17694380
[No Abstract] [Full Text] [Related]
8. Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy.
Neill MG; Wei AC; Jewett MA
Urology; 2007 Jul; 70(1):178.e9-11. PubMed ID: 17656238
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma.
Hutson TE; Bukowski RM
Clin Genitourin Cancer; 2006 Mar; 4(4):296-8. PubMed ID: 16729915
[No Abstract] [Full Text] [Related]
10. Transient sunitinib-induced coma in a patient with fibromyxoid sarcoma.
Arnaud L; Schartz NE; Bousquet G; Sarandi F; Verola O; Madelaine I; Kerob D; Lebbe C
J Clin Oncol; 2008 Mar; 26(9):1569-71. PubMed ID: 18349416
[No Abstract] [Full Text] [Related]
11. The role of tyrosine kinase inhibitors in the treatment of renal cell carcinoma with brain metastases.
Aytekin A; Ciltas A; Sahinli H; Benekli M
J BUON; 2016; 21(1):281-2. PubMed ID: 27061562
[No Abstract] [Full Text] [Related]
12. Fulminant acneiform eruptions after administration of dovitinib in a patient with renal cell carcinoma.
Hsiao YW; Lin YC; Hui RC; Yang CH
J Clin Oncol; 2011 Apr; 29(12):e340-1. PubMed ID: 21263088
[No Abstract] [Full Text] [Related]
13. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Defuentes G; Bladé JS; Berets O
N Engl J Med; 2007 Oct; 357(15):1556-7; author reply 1557-8. PubMed ID: 17928609
[No Abstract] [Full Text] [Related]
14. Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature.
Jhaveri KD; Flombaum CD; Kroog G; Glezerman IG
Nephron Clin Pract; 2011; 117(4):c312-9. PubMed ID: 21051905
[TBL] [Abstract][Full Text] [Related]
15. Newly approved therapies for RCC and their effect on the standard of care.
Figlin RA
Clin Adv Hematol Oncol; 2007 Jan; 5(1):35-6, 66. PubMed ID: 17339824
[No Abstract] [Full Text] [Related]
16. Acute cardiac failure after sunitinib.
Machiels JP; Bletard N; Pirenne P; Jacquet L; Bonbled F; Duck L
Ann Oncol; 2008 Mar; 19(3):597-9. PubMed ID: 18272908
[No Abstract] [Full Text] [Related]
17. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
18. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
Nicholaou T; Wong R; Davis ID
Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435
[No Abstract] [Full Text] [Related]
19. Two new drugs for renal cell carcinoma.
Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624
[No Abstract] [Full Text] [Related]
20. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
